





2024 ASTRO Posters and Presentations



Scarlett Acklin-Wehnert, MD • PQA 03 • September 30 • 8-9 a.m.

Dosimetric Outcomes with the Addition of Interstitial Needles in HDR Brachytherapy for Non-Bulky Cervical Tumor



Mark Chen, MD, PhD • PQA 02 • September 29 • 4:45-6 p.m.

Improving Liver SBRT Target Localization with Hybrid MRI/CBCT Technology

PQA 04 • September 30 • 10:45 a.m.-12 p.m.

Impact of KEAP1/NFE2L2 Mutations on Local Recurrence in Patients Receiving Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases



Junzo Chino, MD • PRO 07 • September 28 • 5:42-6:02 p.m.

Vulvar and Cervical Cancer Treatment Updates



Kai-Cheng Chuang, PhD, MS • PQA 09 • October 1 • 4-5 p.m.

Multi-Channel 3D Convolutional Neural Network to Predict Grade 2 Xerostomia Following Definitive Radiation for Head and Neck Squamous Cell Carcinoma



Christine Eyler, MD, PhD • QP 18 • October 1 • 5:15-6:15 p.m.

Moderator: Bio 5: Genomics and Biomarkers II



John Ginn, PhD • QP 17 • October 1 • 6:05-6:15 p.m.

Orthogonal 2D MR Imaging and Manifold Learning Enables Real-Time 3D Tumor Tracking




Alex Gooding, MD, PhD • PQA 06 • September 30 • 5-6 p.m.

Unbiased Functional Genomics Screen Identifies Unique Therapeutic Vulnerabilities in Osimertinib-Resistant NSCLCs



Emily Harris, MD • PQA 03 • September 30 • 8-9 a.m.

Local Recurrence Rates following Equivocal 3-month Post-Treatment PET after High Dose Rate Brachytherapy for Locally Advanced Cervical Cancer: An Updated Cohort




Christina Huang, MD, MS • SS 27 • September 30 • 5-5:10 p.m.

Long-Term Update of a Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma



Abhishek Kumar, MD, MAS • PQA 08 • October 1 • 2:30-3:45 p.m.

Association of MRI Capsular Involvement and Extraprostatic Extension on Metastasis Free and Overall Survival in Localized Prostate Cancer Treated with Radiation



Dominic LaBella, MD • PQA 08 • October 1 • 2:30-3:45 p.m.

Efficacy of Oligometastasis Directed Stereotactic Body Radiation Therapy in De Novo Oligometastatic Prostate Cancer


PQA 08 • October 1 • 2:30-3:45 p.m.

Efficacy of Oligorecurrence Directed Stereotactic Body Radiation Therapy in Oligorecurrent Prostate Cancer



Nicole Larrier, MD, MS • SS 13 • September 30 • 8-9 a.m.

Moderator: Peds 1: Functional Outcomes and Disease Control Following Multimodality Therapy in Pediatric Oncology



Xinyi Li, PhD • PQA 02 • September 29 • 4:45-6 p.m.

Control Dosimetric Outcome of AI-Generated Plans through OAR Prioritization for Head-and-Neck Cancer: An Investigation on Input Sensitivity



Jim Leng, MD • PQA 10 • October 2 • 10:30-11:45 a.m.

Cost Estimates of Brachytherapy Delivery in Northern Tanzania Using Time-Driven Activity Based Costing



Susan McDuff, MD, PhD • SS 31 • October 1 • 12:45-2 p.m.

Moderator: Breast Cancer 3: Toxicity



Trey Mullikin, MD • PQA 08 • October 1 • 2:30-3:45 p.m.

Comparison of Local Medicare Guidance and Medicare Advantage Plans for Stereotactic Radiosurgery for Brain Metastases



Manisha Palta, MD • EDU 50 • October 1 • 4:32-4:47 p.m.

Finding Clarity in the "Black-Box" of AI and Integration into Clinical Care